Year: 2021

Primary endpoint met with all three CBP-201 arms achieving significant improvements Significant improvements also reported for key secondary endpoints including other measures of skin clearance and itch with CBP-201 300mg every two weeks (Q2W) arm The Company intends to initiate a Phase 3 trial program in mid-2022 SAN DIEGO and TAICANG, SUZHOU, China , Nov. 18, 2021 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported positive topline results from the global Phase 2 clinical trial of CBP-201 administered subcutaneously (SC) to adult patients with...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event. Management provided an in-depth review of the Company’s clinical-stage programs and RNA editing technology platforms.  A webcast replay of the event including slides is available from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Highlights from today’s presentations include the following: Sepofarsen for CEP290-mediated Leber congenital amaurosis 10 (LCA10):The Company expects to report top-line results from the Phase 2/3 Illuminate trial in late Q1/early Q2 2022. The Illuminate trial completed enrollment...

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering price of $40.00 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Apellis to 10,062,500 shares and increased the amount of gross proceeds, before deducting underwriting discounts and commissions and expenses payable by Apellis, to $402.5 million. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. acted as joint book-running managers for...

PALM COAST, Fla., Nov. 18, 2021 (GLOBE NEWSWIRE) — With the help of AllStar Health Brands, GRPS now has purchase orders to begin distributing their gummy products. In addition, AllStar, while developing a dedicated website will engage in an extensive marketing campaign to create awareness for our products. “The feedback we’ve received is exceptional” says Chairman of the Board, Richard Goulding, M.D. “The uniqueness of our products, the focus on real issues for people with problems is a game-changer. www.Vividcbd.com is a website that will help promote the product and how it works. An extensive marketing campaign will be undertaken by AllStar Health Brands to spread the word regarding the products Sleepy Watermelon, Relief Raspberry and Calming Mango.” “We plan to start by using our existing distribution networks and will start...

LAS VEGAS, NV, Nov. 18, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – KYN Capital Group (OTC: KYNC) is pleased to announce its partnering with PXLBRD and Terence Crawford, world champion, 37-0 Professional Boxer, and his various successful ventures. This exclusive NFT collection launches Friday, November 19th, 2021. These NFT’s will commemorate his WBO Welterweight Champion title defense against Shawn Porter the following night, November 20th at the Mandalay Bay Ultra Arena in Las Vegas. Las Vegas is buzzing, hungry, and prepared for this world championship bout. Terence Crawford is the first PXLBRD athlete to develop and sell an NFT and the first athlete to engage KYN Capital Group to assist in advertising, publicity, and the marketing of his entire NFT collection. The Terence Crawford NFT collection includes five unique one-of-one...

LOS ANGELES and DESERT HOT SPRINGS, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Grapefruit USA, Inc. (OTCQB: GPFT) (“Grapefruit” or the “Company”), a premiere California-based cannabis and hemp company, is clarifying the recent sale of stock by company executives. The Company’s executives do not take a salary. Several years ago, they elected to be compensated with the Company’s common stock. The executives favor equity compensation because it is the ultimate incentive to ensure that their interests are fully aligned with the interests of company shareholders – the success of Grapefruit. This form of compensation is also a deliberate management strategy to preserve company cash flow to ensure that it is invested in those projects that are devoted to growing the Company. The sale of all stock takes place under...